Biotechnology

CROs dMed and Clinipace Merge to Accelerate Customer Success

SHANGHAI and MORRISVILLE, N.C., April 28, 2021 /PRNewswire/ -- dMed Global, a full-service Clinical Contract Research Organization (CRO) based inShanghai, China, and Clinipace Incorporated, a full-service Clinical CRO with headquarters inNorth Carolina, USA, announced today that the two companies...

2021-04-28 20:00 1252

Turn Biotechnologies completes latest round of funding

Silicon Valley investor Khosla Ventures joins esteemed group of global investors backing Turn MOUNTAIN VIEW, Calif., April 28, 2021 /PRNewswire/ -- Turn Biotechnologies, a company developing novel RNA medicines for untreatable age-related conditions, today announced that it has closed its latest...

2021-04-28 19:50 1269

DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration as US Study Achieves One-Year Follow-up Milestone

SALT LAKE CITY and TOKYO, April 27, 2021 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it has c...

2021-04-27 09:23 1457

EpiVax Demonstrates Antigen-Specific Tolerance Induction in Allergy with Tregitopes, Results Published in Frontiers in Immunology

PROVIDENCE, R.I., April 27, 2021 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") announces the publication"Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs" inFrontiers in Immunology. This research highlights Tregitopes as a promising therapy for allergy. Administrati...

2021-04-27 09:00 1503

Himalaya Therapeutics Announces Appointment of Brian Zhang as Chief Executive Officer

SAN DIEGO, April 26, 2021 /PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization inGreater China of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, which are based ...

2021-04-26 22:08 1033

One-Stop CLIA Solution with Open Systems and Resources Makes Evolution to Emerging World Healthcare Systems

* Advanced, flexible cooperation models delivered by one-stop CLIA solution can boost government industrialization plans, laboratory technology updates, reagent R&D and localization, and even more investment flows to the industry * COVID-19 NAb Test CLIA Solution coupled with COVID-19 Ag Self ...

2021-04-26 15:17 767

Associates of Cape Cod, Inc. announces launch of PyroSmart NextGen™ Recombinant LAL Reagent

EAST FALMOUTH, Mass., April 23, 2021 /PRNewswire/ -- Associates of Cape Cod, Inc. (ACC), a Seikagaku Group Company, announces the launch of a new, innovative, sustainable recombinant LAL reagent, PyroSmart NextGen™ for Bacterial Endotoxin Testing (BET). The new LAL reagent is sustainably produced...

2021-04-23 22:30 2797

INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800

Given universal eligibility and broad availability of COVID-19 vaccines in the U.S., DoD JPEO-CBRND has notified INOVIO that it will discontinue funding for the Phase 3 INO-4800 trial INOVIO adjusts INO-4800 clinical development strategy to focus on global unmet COVID-19 vaccine needs PLYMOUTH ...

2021-04-23 20:00 2828

The NDA of the Novel Anti-PD-1 mAb Serplulimab of Henlius Accepted by NMPA and Proposed to be Granted Priority Review

SHANGHAI, April 23, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of serplulimab injection (HLX10), a novel anti-PD-1 monoclonal antibody (mAb), for the treatment of unresectable or metastatic microsatellite instability-high (MSI-H) s...

2021-04-23 15:00 1029

The NDA of the Novel Anti-PD-1 mAb Serplulimab of Henlius Accepted by NMPA and Proposed to be Granted Priority Review

SHANGHAI, April 22, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of serplulimab injection (HLX10), a novel anti-PD-1 monoclonal antibody (mAb), for the treatment of unresectable or metastatic microsatellite instability-high (MSI-H) s...

2021-04-22 21:47 1786

RDIF and Minapharm agree to produce over 40 million doses of the Sputnik V vaccine in Egypt

MOSCOW, CAIRO and BERLIN, April 22, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF,Russia's sovereign wealth fund), Egypt's Minapharm, the regional leader in recombinant DNA technology, and itsBerlin-based subsidiary, ProBioGen AG, announce the agreement to produce over 40 million ...

2021-04-22 16:00 1089

Clarivate Releases Predictive Analytics to Help Fuel Life Sciences Deal Making Landscape

Cortellis Deals Intelligence features new trends visualizations and predictive analytics supported by artificial intelligence  LONDON, April 22, 2021 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, t...

2021-04-22 16:00 2254

endpoint Launches ConnectionPOINT™ - A partnership program designed to power accelerated outcomes and move medicine through next-generation eClinical technology interfacing

SAN FRANCISCO, April 21, 2021 /PRNewswire/ -- endpoint Clinical, the leading global interactive response technology (IRT®) company, announced today the launch of their partnership program,ConnectionPOINT™, the first of its kind in the eClinical technology space.  The program's vision is for a g...

2021-04-21 21:00 1695

Seed Health Closes $40 Million in Series A Financing to Launch New Categories, Accelerate Global Distribution and Expand Clinical Research

LOS ANGELES, April 21, 2021 /PRNewswire/ -- Seed Health, a microbial sciences company developing next-generation probiotic applications and live biotherapeutics, today announced the close of a $40 million Series A financing led by impact investor,The Craftory, alongside TechBio investor ARTIS Ven...

2021-04-21 20:00 888

GenScript ProBio Enters Collaboration with Singapore's Experimental Drug Development Centre to Develop Anti-Fibrosis Therapeutic Antibody Programme

SINGAPORE, April 21, 2021 /PRNewswire/ -- GenScript Biotech Corporation (Stock Code: 1548.HK)'s biopharmaceutical CDMO segment, GenScript ProBio announced a collaboration with the Experimental Drug Development Centre (EDDC),Singapore's national platform for drug discovery and development, on an a...

2021-04-21 11:08 2318

Ascentage Pharma to Announce Results from Four Clinical Studies at 2021 ASCO Annual Meeting, with Data of Its Drug Candidates Including Lisaftoclax (APG-2575) to Be Released in Oral Presentations for the First Time

SUZHOU, China and ROCKVILLE, Md., April 21, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that results from four clin...

2021-04-21 08:38 1146

Biovaxys And The World Ovarian Cancer Coalition Join Forces For May 8th, World Ovarian Cancer Day

VANCOUVER, BC and TORONTO, April 20, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancers applications, announced today its sponsorship of this year's World Ovarian Cancer Day, a ...

2021-04-20 20:00 2236

Prenetics Signs Multi-million Dollar Collaboration with Oxford University for Advanced Molecular Diagnostics

* The collaboration is a 3-year joint effort by Prenetics R&D Team, Oxford University and Oxford Suzhou for Advanced Research (OSCAR) for Molecular Diagnostics * A new Prenetics Innovation Technology Centre is established for advanced molecular diagnostics * Collaboration follows successful...

2021-04-20 09:00 958

Himalaya Therapeutics Announces Appointment of Nicholas Desjardins as Chief Financial Officer

SAN DIEGO, April 20, 2021 /PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization inGreater China of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, which are based ...

2021-04-20 01:42 1014

AACR Annual Meeting 2021: AnchorDx Unveils High-Performance Blood Test for Gastric Cancer Screening

GUANGZHOU, China, April 19, 2021 /PRNewswire/ -- At this year's American Association for Cancer Research (AACR) Annual Meeting 2021 (April 10-15), molecular diagnostic company AnchorDx presented a poster (Poster 2610) unveiling its Aurora 2.0 study results. The poster introduced the company's up...

2021-04-19 21:00 999
123456 ... 93